Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-610,355 bronchodilator effects in asthma
NCT00468975Phase 2Completed
- Sponsor
- Pfizer
- Start
- May 2007
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of PF-00610355 in asthma (5 arms), sponsored by Pfizer. Primary endpoint: Forced Expiratory Volume in 1 second. Started May 2007; status: completed.
02
Drugs
PF-00610355
03
Conditions
asthma
Beyond the preview
Go deeper on NCT00468975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00468975.